Survival in COPD patients treated with bronchoscopic lung volume reduction

Hartman, Jorine E.; Welling, Jorrit B A; Klooster, Karin; Carpaij, Orestes A; Augustijn, Sonja W.S.; Slebos, Dirk‐Jan

doi:10.1016/j.rmed.2022.106825

Cited by 28 publications

(21 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COPD is a disease that can be prevented and treated with the characteristics of airflow restriction [ 10 ]. Airflow restriction is not completely reversible and develops continuously, which is related to the abnormal inflammatory response of the lungs to harmful gases or particles such as cigarettes and smoke [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly

Guo

Chen

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Objective. Chronic obstructive pulmonary disease (COPD) is a major and difficult disease of the chronic respiratory system that is common and frequent, with a huge disease burden. The aim of this study was to investigate the efficacy and safety of budesonide/glyburide/formoterol fumarate (BGF) in the treatment of COPD. Methods. A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, and Web of Science. The basic features of the seven pieces of literature were identified using the search strategy. The sample size range was 130∼1264. Results. The effects of BGF increased FEV1 in patients with COPD (mean difference = 2.86, 95%CI: 2.71–3.01, p < 0.00001 ). The effects of BGF improved in patients with ≥1 TEAE in patients with COPD, and was not statistically significant after treatment (Odds rate = 1.00, 95%CI: 0.85–1.17, p = 0.97 ). The effects of BGF increased in patients with TEAEs related a to study treatment in patients with COPD (odds rate = 1.27, 95% CI: 1.03–1.57, p = 0.02 ). The effects of BGF in decreased patients with serious TEAEs in patients with COPD (odds rate = −0.02, 95% CI: −0.03–−0.00, p = 0.04 ). The effects of BGF decreased the death rate in patients with COPD, and were not statistically significant after treatment (odds rate = 0.77, 95% CI: 0.31–1.97, p = 0.59 ). The effects of BGF decreased the hypertension rate in patients with COPD (odds rate = 0.92, 95% CI: 0.44–1.89, p = 0.81 ), and was not statistically significant after treatment. The effects of BGF increased pneumonia in patients with COPD (odds rate = 1.55, 95% CI: 0.81–2.97, p = 0.19 ), and were not statistically significant after treatment. The effects of BGF increased FEV1, increased patients with TEAEs related a to study treatment, and decreased patients with serious TEAEs in patients with COPD. Conclusion. This study elucidates the efficacy and safety of BGF in the treatment of COPD with a view to providing a clinical reference.

show abstract

Section: Introductionmentioning

confidence: 99%

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly

Guo

Chen

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…Furthermore, survival rate at 3-year follow-up was quite high (82%). Previously, we [ 29 ] as well as G arner et al . [ 30 ] found that bronchoscopically reducing lung volume in patients with severe hyperinflation can lead to a survival benefit as well, which can also be an important indicator of long-term treatment efficacy.…”

Section: Discussionmentioning

confidence: 77%

Long-term follow-up after bronchoscopic lung volume reduction valve treatment for emphysema

Hartman

Klooster²,

Koster³

et al. 2022

ERJ Open Res

Self Cite

View full text Add to dashboard Cite

BackgroundMultiple studies have shown that patients with severe emphysema can significantly benefit from the bronchoscopic lung volume reduction treatment with endobronchial valves (EBV) up to 1 year after treatment. However, hardly any data exists on longer term follow-up, especially on quality of life. Our aim was to investigate the long term follow-up after EBV treatment up to 3 years including quality of life in a real life routine clinical setting.MethodsWe retrospectively included patients who underwent EBV treatment in our hospital at least 3 years ago. Patients were invited for annual visits to our hospital and spirometry, bodyplethysmography, 6-min walk distance test (6 MWD) and SGRQ-questionnaire were performed during these visits.ResultsAt one, two and three years of follow-up, data was available from 189, 146 and 112 patients, respectively. FEV1, RV and SGRQ total score significantly improved as compared to baseline up to 3 years after treatment and 6MWD up to 2 years. In general, the magnitude of the improvements gradually decreased over time.ConclusionOur results show that patients can benefit at least up to three years after the EBV treatment. For the first time we found that patients can also benefit in terms of quality of life in the long term which is an important outcome for these group of patients with end-stage COPD.

show abstract

“…More recently, in a study of 1,471 patients, the median survival of patients who underwent treatment with BLVR was found to be longer (1.7 years) compared with those who did not receive the treatment, suggesting that BLVR in patients with severe hyperinflation may also lead to a survival benefit. Notably, BLVR in this study was performed using both valves and coils and was found to be an independent predictor of survival after adjusting for other survival-influencing factors such as age, gender, or severity of disease (10).…”

Section: Review Articlementioning

confidence: 77%

Pneumothorax as a result of bronchoscopic lung volume reduction with endobronchial valves: a clinical practice review of risk and management strategies

Wagh¹,

Ravikumar²,

Hogarth³

2023

Shanghai Chest

View full text Add to dashboard Cite

Bronchoscopic lung volume reduction (BLVR) with endobronchial valves for patients with severe emphysema and absence of collateral ventilation is suggested as a treatment strategy in both the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the National Institute for Health and Care Excellence (NICE) guidelines. BLVR has demonstrated favorable outcomes for patients with severe emphysema by improving lung function, symptoms, quality of life, and possibly mortality. Pneumothorax is the most common complication of BLVR and is caused by the rapid expansion of the ipsilateral non-target lobe with a resulting alveolar or bronchopleural fistula. While concerning due to the potential for short-term acute management, available studies have concluded that pneumothorax following BLVR has not contributed to serious long-term consequences. This article offers a review of the approach to BLVR pre-procedural evaluation and post-procedural management strategies. Additionally, special circumstances including emphysema phenotype, pleural disease, and partial treatment when considering the risk of pneumothorax is also discussed. Initial BLVR pre-procedural evaluation requires a comprehensive history and physical including comorbidities, imaging review, along with assessment of patient function and pulmonary physiology. Post-BLVR procedural monitoring and expert recommendations for pneumothorax management strategies should be followed to help guide clinicians' approach to the care of advanced emphysema patients.

show abstract

Survival in COPD patients treated with bronchoscopic lung volume reduction

Cited by 28 publications

References 21 publications

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly

Long-term follow-up after bronchoscopic lung volume reduction valve treatment for emphysema

Pneumothorax as a result of bronchoscopic lung volume reduction with endobronchial valves: a clinical practice review of risk and management strategies

Contact Info

Product

Resources

About